AUTHORS
Xing Guo, Jingwen Li2, Fangshu Guan3, Hengwei Wu, MD4, Donghua He5, Li Yang6, Wenjun Wu7, Xi Huang, MEd8, Xiaoyan Han, MD,PHD9, Linghui Zhou10, He Huang, MD, PhD11, Zhen Cai, MD,PhD12, Yi Zhao13
AFFILIATIONS
1 Bone Marrow Transplantation Center, The First Affiliated Hospital, Zhejiang University School of Medicine, Hangzhou, China
2 Bone Marrow Transplantation Center, The First Affiliated Hospital, Zhejiang University School of Medicine, Hangzhou, China
3 Bone Marrow Transplantation Center, The First Affiliated Hospital, Zhejiang University School of Medicine, Hangzhou, China
4 Bone Marrow Transplantation Center, The First Affiliated Hospital, Zhejiang University School of Medicine, Hangzhou, China
5 Bone Marrow Transplantation Center, The First Affiliated Hospital, Zhejiang University School of Medicine, Hangzhou, China
6 Bone Marrow Transplantation Center, The First Affiliated Hospital, Zhejiang University School of Medicine, Hangzhou, China
7 Bone Marrow Transplantation Center, The First Affiliated Hospital, Zhejiang University School of Medicine, Hangzhou, China
8 Bone Marrow Transplantation Center, The First Affiliated Hospital, Zhejiang University School of Medicine, Hangzhou, China
9 Bone Marrow Transplantation Center, The First Affiliated Hospital, Zhejiang University School of Medicine, Hangzhou, China
10 Bone Marrow Transplantation Center, The First Affiliated Hospital, Zhejiang University School of Medicine, Hangzhou, China
11 Bone Marrow Transplantation Center, The First Affiliated Hospital, Zhejiang University School of Medicine, Hangzhou, China
12 Bone Marrow Transplantation Center, The First Affiliated Hospital, Zhejiang University School of Medicine, Hangzhou, China
13 Bone Marrow Transplantation Center, The First Affiliated Hospital, Zhejiang University School of Medicine, Hangzhou, China
ABSTRACT
Background Diffuse large B-cell lymphoma (DLBCL) is the most common aggressive B-cell lymphoma, and approximately 40% of patients relapse or become refractory (R/R) after first-line therapy. For transplant-eligible patients, salvage chemotherapy followed by autologous stem-cell transplantation (ASCT) is the standard second-line approach, and the depth of remission achieved before ASCT is a key determinant of outcome. Glofitamab, an off-the-shelf CD20xCD3 bispecific antibody, combined with gemcitabine and oxaliplatin (GemOx) is a recommended option for transplant-ineligible R/R DLBCL. GDP (gemcitabine, dexamethasone, cisplatin) is a widely used, highly active salvage backbone in R/R DLBCL. We therefore conducted a prospective study to evaluate the efficacy and safety of glofitamab plus GDP (Glofit-GDP) in R/R DLBCL, including its potential to bridge transplant-eligible patients to ASCT.
Method This prospective, multicenter, single-arm, phase II study (ChiCTR2600116920) enrolls patients aged 18 years or older with R/R DLBCL, regardless of transplant eligibility; planned enrollment is 43. It was approved by the ethics committee of the First Affiliated Hospital, Zhejiang University School of Medicine, and registered in the Chinese Clinical Trial Registry. Treatment is given in 21-day cycles: obinutuzumab 1000 mg on cycle 1 day 1(C1D1), glofitamab step-up dosing (2.5 mg on C1D8, 10 mg on C1D15, then 30 mg on C2D1 onward), and GDP from day 2 (gemcitabine 1 g/m2 on D2 and D9, cisplatin 75 mg/m2 on D2, and dexamethasone 40 mg/d on D2-5), with chemotherapy doses adjusted by the investigator for age and performance status. Response is assessed after 3 induction cycles, and transplant-eligible patients achieving partial or complete response proceed to ASCT. The primary endpoint is objective response rate (ORR) after 3 induction cycles; secondary endpoints include complete response rate (CRR) ,transplant conversion rate, event-free survival, 24-month progression-free survival, overall survival, and safety. Responses were assessed by PET/CT per the Lugano criteria, adverse events graded per CTCAE v5.0, and cytokine release syndrome (CRS) per ASTCT criteria. Exploratory circulating tumor DNA (ctDNA) was assessed in a subset of patients.
Result Between January and July 2026, 15 patients were enrolled. The median age was 72 years (range, 48-82) and 11 (73%) were male. Baseline features were predominantly high-risk: Ann Arbor stage IV (n=8, 53%), ECOG performance status 0-1 (n=13, 87%), International Prognostic Index 3-4 (n=8, 53%), non-germinal-center B-cell subtype (n=12, 80%), and double-expressor lymphoma (n=5, 33%). All 15 patients were naive to both CAR T-cell therapy and ASCT. The median number of prior lines was 1 (range, 1-3), with 67% receiving only one prior line; 8 patients (53%) had relapsed after and 7 (47%) were refractory to their last line of therapy. At data cutoff, 8 patients had reached the first response assessment: all achieved an objective response (ORR 100%, 8/8), including 6 who achieved a complete response (CRR 75%, 6/8). Among the patients with a complete response, 2 underwent ctDNA testing, both detectable at baseline, and both became undetectable after 3 cycles. 8 patients were included in the safety analysis. Hematologic toxicity predominated: any-grade leukopenia/neutropenia in 7 (88%), with grade 3-4 leukopenia in 5 (63%) and grade 3-4 neutropenia in 7 (88%); anemia in 7 (88%); and thrombocytopenia in all 8 (100%), grade 3-4 in 5 (63%). CRS occurred in 5 patients (63%; four grade 1, one grade 2), all after the 2.5 mg glofitamab dose and resolving with supportive care; no immune effector cell-associated neurotoxicity syndrome (ICANS) occurred. Infections comprised one case each of parainfluenza, herpes zoster, and cytomegalovirus reactivation, all resolving with antiviral therapy. Grade 1 renal insufficiency, possibly cisplatin-related, occurred in 2 patients (25%), resolving in one and ongoing in the other.
Conclusion These preliminary results show that Glofit-GDP produces a high response rate (ORR 100%, CRR 75%) with a manageable, predominantly hematologic safety profile and no grade 3 or higher CRS in R/R DLBCL. Enrollment and follow-up are ongoing, and updated efficacy, survival, and transplant-conversion data will be presented.
DISCLOSURES
Xing Guo: No relevant conflicts of interest to declare.